Your browser doesn't support javascript.
loading
Treatment with gentamicin-impregnated collagen sponges in reducing infection of implantable cardiac devices: 10-year analysis with propensity score matching.
Matteucci, Andrea; Bonanni, Michela; Massaro, Gianluca; Chiricolo, Gaetano; Stifano, Giuseppe; Forleo, Giovanni Battista; Biondi-Zoccai, Giuseppe; Sangiorgi, Giuseppe.
Afiliação
  • Matteucci A; Division of Cardiology, University Hospital "Tor Vergata", Rome, Italy; Division of Cardiology, San Filippo Neri Hospital, Via Martinotti, 20, Rome, Italy. Electronic address: andrea.matteucci2@gmail.com.
  • Bonanni M; Division of Cardiology, University Hospital "Tor Vergata", Rome, Italy.
  • Massaro G; Division of Cardiology, University Hospital "Tor Vergata", Rome, Italy.
  • Chiricolo G; Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy.
  • Stifano G; Division of Cardiology, University Hospital "Tor Vergata", Rome, Italy.
  • Forleo GB; Arrhythmology, Luigi Sacco Hospital, Milan, Italy.
  • Biondi-Zoccai G; Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy; Mediterranea Cardiocentro, Napoli, Italy.
  • Sangiorgi G; Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy.
Rev Port Cardiol ; 42(8): 711-717, 2023 08.
Article em En, Pt | MEDLINE | ID: mdl-37085085
INTRODUCTION AND OBJECTIVES: The incidence of device infection has increased over time and is associated with increased mortality in patients with cardiac implantable electronic devices (CIEDs). Gentamicin-impregnated collagen sponges (GICSs) are useful in preventing surgical site infection (SSI) in cardiac surgery. Nevertheless, to date, there is no evidence concerning their use in CIED procedures. Our study aims to determine the effectiveness of treatment with GICSs in preventing CIED infection. METHODS: A total of 2986 adult patients who received CIEDs between 2010 and 2020 were included. Before device implantation, all patients received routine periprocedural systemic antibiotic prophylaxis. The study endpoints were the CIED infection rate at one year and the effectiveness of the use of GICSs in reducing CIED infection. RESULTS: Among 1524 pacemaker, 942 ICD and 520 CRT implantations, CIED infection occurred in 36 patients (1.2%). Early reintervention (OR 9 [95% CI 3.180-25.837], p<0.001), pocket hematoma (OR 11 [95% CI 4.195-28.961], p<0.001), diabetes (OR 2.9 [95% CI 1.465-5.799], p=0.002) and prolonged procedural time (OR 1.02 [95% CI 1.008-1.034], p=0.001) were independent risk factors for CIED infection. Treatment with GICSs reduced CIED infections significantly ([95% CI -0.031 to -0.001], p<0.001). CONCLUSIONS: The use of GICSs may help in reducing infections associated with CIED implantation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Infecções Relacionadas à Prótese / Desfibriladores Implantáveis Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En / Pt Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Infecções Relacionadas à Prótese / Desfibriladores Implantáveis Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En / Pt Ano de publicação: 2023 Tipo de documento: Article